Stock TRAW TRAWS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Market Closed - Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
0.3999 USD +9.56% Intraday chart for Traws Pharma, Inc. -9.32% -46.37%
Jul. 02 Traws Pharma Files for Potential Sale of 128.9 Million Shares MT
May. 15 Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Traws Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

eece6d9baaade1c88a.URyQurZMhlx5Vk7_bYCeJZNXmg92Oumb5-kCpcpMiLw.FGjajZsJ4WkBEHa5XczOTPYu3W4nbtDdk4805J9_0uYeWOLx2jS2OSwCBw~4653e35bb2ad4e03db51d60d21e28cb3

Analyst Recommendations on Traws Pharma, Inc.

Traws Pharma Files for Potential Sale of 128.9 Million Shares MT
HC Wainwright Upgrades Onconova Therapeutics to Buy From Neutral, Price Target is $11 MT
Ladenburg Thalmann Starts Onconova Therapeutics at Buy With $7 Price Target MT
ONCONOVA THERAPEUTICS : Guggenheim Starts Onconova Therapeutics at Buy With $4 Price Target MT
ONCONOVA THERAPEUTICS : Noble Capital Upgrades Onconova Therapeutics to Outperform From Market Perform, Adjusts Price Target to $0.46 From $0.30 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.3999 USD
Average target price
8 USD
Spread / Average Target
+1,900.50%
High Price Target
11 USD
Spread / Highest target
+2,650.69%
Low Price Target
6 USD
Spread / Lowest Target
+1,400.38%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Traws Pharma, Inc.

HC Wainwright
Ladenburg Thalmann
Guggenheim

Ratings for Traws Pharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TRAW Stock
  4. Consensus Traws Pharma, Inc.